This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LMDX LumiraDx (LMDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About LumiraDx Stock (NASDAQ:LMDX) Get LumiraDx alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.0076▼$0.016052-Week Range N/AVolume132.24 million shsAverage Volume56.75 million shsMarket Capitalization$5.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom. Read More Receive LMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LMDX Stock News HeadlinesFormer Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic PlatformMarch 17, 2025 | businesswire.comLumiraDx Ltd LMDXFApril 14, 2024 | morningstar.comMTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 17 at 2:00 AM | Porter & Company (Ad)LMDX.OJanuary 31, 2024 | reuters.comWhy LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving PremarketJanuary 8, 2024 | msn.comWhy Is LumiraDx (LMDX) Stock Down 13% Today?January 8, 2024 | investorplace.comLumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thJanuary 5, 2024 | finance.yahoo.comRoche (RHHBY) to Acquire LumiraDx's Point of Care TechnologyJanuary 2, 2024 | msn.comSee More Headlines LMDX Stock Analysis - Frequently Asked Questions How were LumiraDx's earnings last quarter? LumiraDx Limited (NASDAQ:LMDX) posted its quarterly earnings results on Thursday, August, 24th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. The company earned $21 million during the quarter, compared to the consensus estimate of $21.07 million. What other stocks do shareholders of LumiraDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that LumiraDx investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), Abbott Laboratories (ABT), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Wayfair (W). Company Calendar Last Earnings8/24/2023Today9/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LMDX CIK1685428 Webwww.lumiradx.com Phone354-640-0540FaxN/AEmployees1,210Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$447.79 million Net Margins-268.45% Pretax Margin-264.58% Return on EquityN/A Return on Assets-77.91% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.23 Sales & Book Value Annual Sales$126.52 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / BookN/AMiscellaneous Outstanding Shares318,546,000Free Float205,749,000Market Cap$5.10 million OptionableNot Optionable Beta1.73 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:LMDX) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LumiraDx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share LumiraDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
